44 research outputs found
Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints
Aaron Kesselheim and colleagues analyzed unsealed whistleblower complaints
against pharmaceutical companies filed in US federal fraud cases that contained
allegations of off-label marketing, and develop a taxonomy of the various
off-label practices
Recommended from our members
Resting state cortico-thalamic-striatal connectivity predicts pesponse to dorsomedial prefrontal rTMS in major depressive disorder
Despite its high toll on society, there has been little recent improvement in treatment efficacy for Major Depressive Disorder (MDD). The identification of biological markers of successful treatment response may allow for more personalized and effective treatment. Here we investigate whether resting state functional connectivity predicted response to treatment with rapid transcranial magnetic stimulation (rTMS) to dorsomedial prefrontal cortex (dmPFC). Twenty five individuals with treatment-refractory MDD underwent a 4-week course of dmPFC-rTMS. Before and after treatment, subjects received resting state functional MRI scans and assessments of depressive symptoms using the Hamilton Depresssion Rating Scale (HAMD17). We found that higher baseline cortico-cortical connectivity (dmPFC-subgenual cingulate and subgenual cingulate to dorsolateral PFC) and lower cortico-thalamic, cortico-striatal and cortico-limbic connectivity were associated with better treatment outcomes. We also investigated how changes in connectivity over the course of treatment related to improvements in HAMD17 scores. We found that successful treatment was associated with increased dmPFC-thalamic connectivity and decreased sgACC-caudate connectivity, Our findings provide insight into which individuals might respond to rTMS treatment and the mechanisms through which these treatments work
Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study
“Snake-oil,” “quack medicine,” and “industrially cultured organisms:” biovalue and the commercialization of human microbiome research
Effectiveness of psychosocial interventions in eating disorders: an overview of Cochrane systematic reviews
Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature
A systematic search of the literature reveals limited evidence to support use of
aripiprazole, a second-generation antipsychotic medication, in maintenance
therapy of bipolar disorder, despite widespread use
Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo-controlled multi-Centre trial: TCC:PAINDIP
__Abstract__
Background: The comorbidity of pain and depression is associated with high disease burden for patients in terms
of disability, wellbeing, and use of medical care. Patients with major and minor depression often present
themselves with pain to a general practitioner and recognition of depression in such cases is low, but evolving.
Also, physical symptoms, including pain, in major depressive disorder, predict a poorer response to treatment. A
multi-faceted, patient-tailored treatment programme, like collaborative care, is promising. However, treatment of
chronic pain conditions in depressive patients has, so far, received limited attention in research. Cost effectiveness
of an integrated approach of pain in depressed patients has not been studied.
This article describes the aims and design of a study to evaluate effects and costs of collaborative care with the
antidepressant duloxetine for patients with pain symptoms and a depressive disorder, compared to collaborative
care with placebo and compared to duloxetine alone